Live tape
Top 8, mentions 7d30,017NVDA14,564 mentions▲ +0.04ANT4,160 mentions▲ +0.06GOOGL2,936 mentions▲ +0.04SPY2,248 mentions▲ +0.05QQQ1,804 mentions▲ +0.04SPCX1,748 mentions▲ +0.08AMD1,367 mentions▲ +0.06AAPL1,190 mentions▲ +0.04

Equity · Healthcare

VYGR

NASDAQ

Voyager Therapeutics (VYGR)

3.17 USD +4.45% vs prior close
Voyager Therapeutics, Inc. price graph

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers.

Market cap
197.3M USD
Revenue, year to Dec 2025
40.4M USD
EPS, diluted, year to Dec 2025
−2.04 USD
52-week range
3 USD – 5.33 USD
Avg volume
164.6K

as of Jul 17, 2026

Have Voyager Therapeutics (VYGR) insiders bought or sold shares recently?

In the 90 days to 22 Nov 2026, no Voyager Therapeutics insider bought or sold shares on the open market; all 2 Form 4 filings in that window were grants, exercises, tax withholding or transfers (SEC Form 4).

Form 4, 90 days to 22 Nov 2026, newest Form 4 filing 1 Nov 2026

0buys
0sells
2other filings
Have Voyager Therapeutics (VYGR) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
01 Nov 2026Carter Todd AlfredChief Scientific OfficerAward33,000
01 Nov 2026Swartz RobinPresidentAward68,250

Which funds hold Voyager Therapeutics (VYGR)?

8 of the 45 institutional funds we track reported a Voyager Therapeutics position for the quarter ended 30 Sep 2026 — a combined 19.1M USD; the latest of those filings landed 16 Nov 2026.

Form 13F

Which funds hold Voyager Therapeutics (VYGR)?
FundPositionSharesValueShares q/q
Millennium ManagementHeld (±25%)4,878,20813.1M USD+9.8%
Two Sigma InvestmentsHeld (±25%)843,6662.3M USD−11.1%
Renaissance TechnologiesHeld (±25%)406,6041.1M USD−17.9%
Citadel AdvisorsTrimmed323,918868K USD−58.7%
Point72 Asset ManagementHeld (±25%)278,800747K USD+18.1%
Marshall WaceAdded215,856578K USD+54.8%
AQR Capital ManagementTrimmed163,187437K USD−54.2%
D. E. Shaw & Co.Trimmed18,96351K USD−86.8%

What has been filed or recorded for Voyager Therapeutics (VYGR)?

The filings we hold for Voyager Therapeutics, newest first: 2 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 14 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Voyager Therapeutics (VYGR)?
And
14 Oct 2026Fails to deliverShares failed to deliver175 shares376 USD notional · <0.001% of shares out
13 Oct 2026Fails to deliverShares failed to deliver175 shares397 USD notional · <0.001% of shares out
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS −0.40 USD
30 Sep 2026FinancialsTotal assets177.1M USDat period end
30 Sep 2026FinancialsTotal equity135.1M USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −0.40 USD
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −0.47 USD
31 Dec 2025Annual reportFY 2025 reportedEPS −2.04 USD
31 Dec 2025FinancialsRevenue40.4M USDfiscal year
31 Dec 2025FinancialsNet income−119.7M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−2.04 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −0.47 USD
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −0.57 USD
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −0.53 USD
31 Dec 2024Annual reportFY 2024 reportedEPS −1.13 USD

What do people ask about Voyager Therapeutics (VYGR)?

From live data
What is Voyager Therapeutics’ market cap?197.3M

Voyager Therapeutics is worth 197.3M USD by market value as of 17 Jul 2026, which is the share price times the shares on issue from its SEC filings.

What is Voyager Therapeutics’ revenue?40.4M

Voyager Therapeutics reported revenue of 40.4M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings

Have Voyager Therapeutics insiders bought or sold shares recently?2 filings

In the 90 days to 22 Nov 2026, no Voyager Therapeutics insider bought or sold shares on the open market; all 2 Form 4 filings in that window were grants, exercises, tax withholding or transfers (SEC Form 4). See Insiders

Which funds own Voyager Therapeutics?8 of 45

8 of the 45 funds we track reported a Voyager Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Millennium Management, Two Sigma Investments and Renaissance Technologies. See Funds

When did Voyager Therapeutics last report earnings?−0.40

Voyager Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.40 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  7. SEC EDGARreported earnings figures and scheduled report dates
  8. SEC EDGARValuation computed from SEC EDGAR filings
  9. SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words